Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Alzheimers Disease: early-phase trial registry
30 of 145 indexed Alzheimers Disease trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #79 of 28,963 conditions by registered trial count.
145 US clinical trials · 30 currently recruiting · #79 of 28,963 conditions by registered trial count
Alzheimers Disease: 145 US clinical trials tracked, 30 recruiting.
Alzheimers Disease is the subject of 145 registered US clinical trials on ClinicalTrials.gov, 30 of them currently open to new participants. 25 are in Phase 3-4 (later-stage) and 74 in Phase 1-2 (earlier-stage). The most active sponsor is Eli Lilly and Company, running 8 of these trials.
Open enrollment, early-phase tilt
Alzheimers Disease has 145 registered US clinical trials, 30 of them open to new participants right now, about 21% of the total.
- 30
- recruiting participants now
- 21%
- of trials open to enrollment
- 25
- in Phase 3-4 (later-stage)
- 8
- top sponsor: Eli Lilly and Company
Corpus placement: #79 of 28,963 conditions by registered trial count on ClinicalTrials.gov-derived indexes. Registry reference only, not medical advice.
Key findings
What ClinicalTrials.gov does not surface for Alzheimers Disease on its own pages , computed from the registry mirror as of 2026-07-11. Each line carries its own denominator so it can be quoted as it stands.
-
Alzheimers Disease is recruiting below its size-band peers.
30 of 145 indexed trials (20.7%) are open to enrollment, against a 37.2% average across 135 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Alzheimers Disease trials is spread across many organizations.
Eli Lilly and Company accounts for 8 of 145 trials (5.5%). 86 distinct sponsors appear on at least one study for this condition label.
-
Typical Alzheimers Disease enrolment sits around 107 participants.
Median target enrolment is 107 among the 143 trials that report a genuine target (sentinel values excluded). 66 of those (46.2%) plan for fewer than 100 participants.
-
Alzheimers Disease research is mostly interventional.
119 interventional and 26 observational studies make up this index (82.1% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
145 total, page 3 of 3
Nefiracetam in the Treatment of Alzheimer's Disease
National Institute of Neurological Disorders and Stroke (NINDS)
NCT00001933
Safety Study of Nicotinamide to Treat Alzheimer's Disease
University of California, Irvine
NCT00580931
Effects of LY450139 Dihydrate on Subjects With Mild to Moderate Alzheimer's Disease
Eli Lilly and Company
NCT00244322
Study of the Safety & Efficacy of Leukine® in the Treatment of Alzheimer's Disease
University of Colorado, Denver
NCT01409915
Distance Savvy: Testing Tele-Savvy, a Distance Dementia Family Caregiver Education Program
Emory University
NCT02300584
A Safety Study of LY2886721 Multiple Doses in Healthy Subjects
Eli Lilly and Company
NCT01227252
Cerebrospinal Fluid (CSF) Biomarkers Alzheimer's Disease (AD) and Non-AD Dementias
Duke University
NCT01730430
MRI of Alzheimer's Disease Imaging Amyloid Plaques in Persons With and Without Memory Problems
National Institute of Neurological Disorders and Stroke (NINDS)
NCT00413621
Multiple Ascending Dose Study of TC-5619 in Healthy Elderly Subjects and Subjects With Alzheimer's Disease
Targacept
NCT01254448
Study of Nasal Insulin to Fight Forgetfulness - Long-acting Insulin Detemir - 120 Days (SL120)
Wake Forest University Health Sciences
NCT01595646
A Single Ascending Dose Study to Investigate the Safety, Tolerability, Immunogenicity and Pharmacokinetics of Intravenously Administered RO7126209 in Healthy Participants
Hoffmann-La Roche
NCT04023994
Relative Bioavailability Study of Four Experimental Formulations for Alzheimer's Disease
Bristol-Myers Squibb
NCT00901498
Tau Imaging in Professional Fighters
Avid Radiopharmaceuticals
NCT02278354
Study of ITI-007 in Healthy Geriatric Volunteers and in Geriatric Patients With Dementia
Intra-Cellular Therapies
NCT02078310
BPN14770 Single Ascending Dose Study in Healthy Male and Female Subjects
Tetra Discovery Partners
NCT02648672
Memory and Insulin in Early Alzheimer's Disease
Jeff Burns, MD
NCT00581867
Evaluation of [123I] AV83 and SPECT in Patients With Alzheimer Disease in Comparison to Healthy Controls
Molecular NeuroImaging
NCT00448799
A Trial of 18F-AV-133 and 18F-AV-45 Positron Emission Tomography (PET)
Avid Radiopharmaceuticals
NCT01503944
A Safety and Tolerability Study of ABT-126 in Elderly
Abbott
NCT00867399
Practice Effects and Amyloid Imaging Using 18F-PIB or Flutemetamol PET and FDG-PET
University of Utah
NCT01202994
A Study of 18F-AV-45 in Alzheimer's Disease (AD) and Healthy Volunteers
Avid Radiopharmaceuticals
NCT01565343
A Study to Evaluate the Effect of Heat Application on the Delivery Profile of Corplex™ Donepezil Transdermal Delivery System (TDS)
Corium
NCT03438604
Safety and Tolerability of AZD0530 (Saracatinib) in Alzheimer's Disease
Stephen M. Strittmatter
NCT01864655
Wii-fit for Activity, Balance and Gait in Assisted Living
University of Nebraska
NCT01000038
A Phase 1, Non-Randomized, Open-Label, Single-Dose Study To Evaluate The Pharmacokinetics, Safety, And Tolerability Of Dimebon [PF 01913539] In Subjects With Severely-Impaired And Normal Renal Function
Pfizer
NCT00824590
Effect of Insulin Sensitizer Metformin on AD Biomarkers
University of Pennsylvania
NCT01965756
Creatine to Augment Bioenergetics in Alzheimer's
University of Kansas Medical Center
NCT05383833
A Study In Healthy Volunteers To Estimate The Pharmacokinetics Of Four Modified-Release Formulations Of Dimebon (Latrepirdine)
Pfizer
NCT00988624
Paired Integrative Home Exercise for Seniors With Dementia and Their Caregivers (PairedPLIE)
University of California, San Francisco
NCT02403752
Bexarotene Amyloid Treatment for Alzheimer's Disease
The Cleveland Clinic
NCT01782742
"Healthy Actions and Lifestyles to Avoid Dementia or Hispanos y el ALTo a la Demencia Program"
Alzheimer's Disease Cooperative Study (ADCS)
NCT05350410
In Vivo Imaging of Therapeutic Electric Current Flow
University of Florida
NCT02453763
Study Evaluating SRA-333 in Mild to Moderate Alzheimer's Disease (AD)
Wyeth is now a wholly owned subsidiary of Pfizer
NCT00151333
A Brief Study To Evaluate The Safety, Tolerability, And Blood Levels Of Multiple Doses Of PF-044467943 Or Placebo In Combination With Donepezil In Subjects With Mild To Moderate Alzheimer's Disease
Pfizer
NCT00988598
Using a Wireless Controller to Deliver a Lighting Intervention to Persons With Dementia
Icahn School of Medicine at Mount Sinai
NCT05519137
A Phase 1, Randomized, Open-Label, Two-Way Crossover Study To Evaluate The Steady-State Effect Of Dimebon (PF 01913539) On The Single-Dose Pharmacokinetics And Pharmacodynamics Of Warfarin In Healthy Subjects
Pfizer
NCT00827034
A Study to Evaluate the Effect of Bexarotene on Beta-Amyloid and Apolipoprotein E Metabolism in Healthy Subjects
ReXceptor
NCT02061878
Down Syndrome Biomarker Initiative (DSBI)
Michael Rafii
NCT02141971
Safety and Effectiveness Study of Intranasal Insulin Glulisine on Cognitive and Memory in Mild-Mod AD Patients.
HealthPartners Institute
NCT01436045
CERE-110 in Subjects With Mild to Moderate Alzheimer's Disease
Sangamo Therapeutics
NCT00087789
Oxaloacetate Pharmacokinetics and Safety
Russell Swerdlow, MD
NCT02063308
Efficacy and Safety of MNI-672 SPECT for Detection/Exclusion of Cerebral B-amyloid in AD Subjects Compared to HVs.
Molecular NeuroImaging
NCT01859767
Venlafaxine for Depression in Alzheimer's Disease (DIADs-3)
Johns Hopkins University
NCT01609348
Development and Decline of Brain and Cognition Through the Life Span
National Institute of Mental Health (NIMH)
NCT00880451
Gene-Environment Interactions in Alzheimer's Disease
US Department of Veterans Affairs
NCT00018473
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 35 |
| Phase 2 | 39 |
| Phase 3 | 25 |
Top Sponsors
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
What is open for Alzheimers Disease right now
30 recruiting of 145 indexed (21% open).
Phase mix: 25 late (III/IV) vs 74 early (I/II) (early-phase heavy).
Top sponsor: Eli Lilly and Company (8 trials), 9 others listed. 45 shown below, recruiting first. #79 of 28,963 conditions by registered trial count.
How open-enrollment share is computed
Open share is recruiting_count divided by trial_count for this condition label in the public registry export. Status can change between pulls; treat the figure as a snapshot of research attention, not treatment availability.
Frequently Asked Questions
How many clinical trials are there for Alzheimers Disease?
PlainTrial tracks 145 US clinical trials for Alzheimers Disease, of which 30 are currently recruiting participants. Data sourced from ClinicalTrials.gov.
How do I find a recruiting trial for Alzheimers Disease?
Use the trial list above filtered by "Recruiting" status, or visit our trial finder at /recruiting to search by condition and state. Always discuss trial participation with your healthcare provider before enrolling.
Is this data current?
Data is sourced from ClinicalTrials.gov and reflects our most recent data pull. Trial status may have changed since then. Always verify current information at ClinicalTrials.gov before making decisions about participation.
Related
Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from ClinicalTrials.gov (National Library of Medicine). Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Source: ClinicalTrials.gov (NIH/NLM) ClinicalTrials.gov AACT registry · 2026 Trial counts and statuses sourced from ClinicalTrials.gov. Sponsor counts include both industry and federal/academic sponsors.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page aggregates every registered trial for this condition, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.